Endothelin receptor antagonists as antihypertensives: the next frontier

References

• Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet365, 217–223 (2005).
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one-million adults in 61 prospective studies. Lancet360, 1903–1913 (2002).
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Ninomiya T et al. Effects of different regimens to lower blood pressure on major cardiovasculer events in older and younger adults: meta-analysis of randomized trials. BMJ336, 1121–1123 (2008).
   PubMed Web of Science ®Google Scholar
• Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension49, 69–75 (2007).
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Li S, Chen SC et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am. J. Med.121, 332–340 (2008).
   PubMed Web of Science ®Google Scholar
• ALLHAT investigators. Major-outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA288, 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-Dehoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA290, 2805–2816 (2003).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on the detection, evaluation, and treatment of high blood pressure: the JNC7 report. JAMA289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation117, E510–E526 (2008).
   PubMed Web of Science ®Google Scholar
• Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. N. Engl. J. Med.355, 385–392 (2006).
   PubMed Web of Science ®Google Scholar
• Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N. Engl. J. Med.338, 784–790 (1998).
   PubMed Web of Science ®Google Scholar
• Nakov R, Pfarr E, Eberle S. Darusentan: an effective endothelin A receptor antagonist for the treatment of hypertension. Am. J. Hypertens.15, 583–589 (2002).
   PubMed Web of Science ®Google Scholar
• Raichlin E, Prasad A, Mathew V et al. Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension52, 522–528 (2008).
   PubMed Web of Science ®Google Scholar
• Black HR, Bakris GL, Weber MA et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J. Clin. Hypertens.9, 760–769 (2007).
   PubMedGoogle Scholar
• Liu C, Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst. Rev.3, CD004434 (2006).
   Google Scholar
• Rothermund L, Traupe T, Dieterich M et al. Nephroprotective effects of the endothelin ETA receptor antagonist darusentan in salt-sensitive genetic hypertension. Eur. J. Pharmacol.468, 209–216 (2003).
   PubMed Web of Science ®Google Scholar
• Nelson JB, Love W, Chin JL et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer113, 2478–2487 (2008).
   PubMed Web of Science ®Google Scholar
• Richetta AG, Mattozzi C, Maiani E et al. Efficacy of Bosentan in treatment of refractory sclerodermic bone prominences skin ulcers. Clin. Ther.159, 317–319 (2008).
   Google Scholar
• Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can. J. Physiol. Pharmacol.86, 485–498 (2008).
   PubMed Web of Science ®Google Scholar
• Guo C, Rabinovitch M. A novel chymase cDNA cloned from rat pulmonary artery smooth muscle cells with increased vascular expression in spontaneously hypertensive rats. Circulation98, I-745 (Abstract) (1998).
   Google Scholar
• Ikeda K, Emoto N, Raharjo SB et al. Molecular identification and characterization of novel membrane-bound metalloprotease, the soluble secreted form of which hydrolyzes a variety of vasoactive peptides. J. Biol. Chem.274, 32469–32477 (1999).
   PubMed Web of Science ®Google Scholar
• Yanagisawa H, Hammer RE, Richardson JA et al. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J. Clin. Invest.105, 1373–1382 (2000).
   PubMed Web of Science ®Google Scholar
• Seyrantepe V, Hinek A, Peng J et al. Enzymatic activity of lysosomal carboxypeptidase (cathepsin) A is required for proper elastic fiber formation and inactivation of endothelin-1. Circulation117, 1973–1981 (2008).
   PubMed Web of Science ®Google Scholar
• Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu. Rev. Pharmacol. Toxicol.41, 851–876 (2001).
   PubMed Web of Science ®Google Scholar
• Shreenivas S, Oparil S. The role of endothelin-1 in human hypertension. Clin. Hemorheol. Microcirc.37, 157–178 (2007).
   PubMed Web of Science ®Google Scholar
• Lüscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation102, 2434–2440 (2000).
   PubMed Web of Science ®Google Scholar
• Douglas SA, Nambi P, Gellai M et al. Pharmacologic characterization of the novel, orally available endothelin-A – selective antagonist SB 247083. J. Cardiovasc. Pharmacol.31(Suppl. 1), S273–S276 (1998).
   Google Scholar
• Givertz MM, Colucci WS, LeJemtel TH et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation101, 2922–2927 (2000).
   PubMed Web of Science ®Google Scholar
• Motte S, McEntee K, Naeije R. Endothelin receptor antagonists. Pharmacol. Ther.110, 386–414 (2006).
   PubMed Web of Science ®Google Scholar
• Davenport AP, O’Reilly G, Molenaar P et al. Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle. J. Cardiovasc. Pharmacol.22, S22–S25 (1993).
   Google Scholar
• Opitz CF, Ewert R. Dual ETA/ETB vs. selective ETA endothelin receptor antagonism in patients with pulmonary hypertension. Eur. J. Clin. Invest.36(Suppl. 3), 1–9 (2006).
   PubMed Web of Science ®Google Scholar
• Rubanyi GM, Polokoff M. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev.46, 325–415 (1994).
   PubMed Web of Science ®Google Scholar
• Ge Y et al. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am. J. Physiol. Renal Physiol.291, F1274–F1280 (2006).
   PubMed Web of Science ®Google Scholar
• Abassi ZA, Ellahham S, Winaver J, Hofman A. The intrarenal endothelin system and hypertension. News Physiol. Sci.6, 52–56 (2001).
   Google Scholar
• Dhaun N, Goddard J, Kohan DE, Pollock DM, Schiffrin EL, Webb DJ. Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension52, 452–459 (2008).
   PubMed Web of Science ®Google Scholar
• Larivie`re R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension21, 294–300 (1993).
   PubMed Web of Science ®Google Scholar
• Larivie`re R, Day R, Schiffrin EL. Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension21, 916–920 (1993).
   PubMed Web of Science ®Google Scholar
• Li J-S, Larivie`re R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in DOCA-salt hypertensive rats: evidence for a role of endothelin in vascular hypertrophy. Hypertension24, 183–188 (1994).
   PubMed Web of Science ®Google Scholar
• Schiffrin EL, Larivie`re R, Li JS, Sventek P, Touyz RM. Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension25, 769–773 (1995).
   PubMed Web of Science ®Google Scholar
• Doucet J, Gonzalez W, Michel JB. Endothelin antagonists in salt-dependent hypertension associated with renal insufficiency. J. Cardiovasc. Pharmacol.27, 643–651 (1996).
   PubMed Web of Science ®Google Scholar
• Sventek P, Turgeon A, Garcia R, Schiffrin EL. Vascular and cardiac overexpression of endothelin-1 gene in one-kidney one clip Goldblatt hypertensive rats but only in the late phase of two-kidney one clip Goldblatt hypertension. J. Hypertens.14, 57–64 (1996).
   PubMed Web of Science ®Google Scholar
• Sharifi AM, He G, Touyz RM, Schiffrin EL. Vascular endothelin-1 gene expression and effect of an endothelin A receptor antagonist on structure and function of small arteries from stroke-prone spontaneously hypertensive rats. J. Cardiovasc. Pharmacol.31(Suppl. 1), S309–S312 (1998).
   Google Scholar
• Schiffrin EL. State-of-the-art lecture. Role of endothelin-1 in hypertension. Hypertension34, 876–881 (1999).
   PubMed Web of Science ®Google Scholar
• Schiffrin EL, Turgeon A, Deng LY. Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats. Br. J. Pharmacol.121, 935–940 (1997).
   PubMed Web of Science ®Google Scholar
• Schiffrin EL, Sventek P, Li JS, Turgeon A, Reudelhuber T. Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats. Br. J. Pharmacol.115, 1377–1381 (1995).
   PubMed Web of Science ®Google Scholar
• Li JS, Schürch W, Schiffrin EL. Renal and vascular effects of chronic endothelin receptor antagonism in malignant hypertensive rats. Am. J. Hypertens.9, 803–811 (1996).
   PubMed Web of Science ®Google Scholar
• D’Uscio LV, Barton M, Shaw S, Moreau P, Lüscher TF. Structure and function of small arteries in salt-induced hypertension: effects of chronic endothelin-subtype-A-receptor blockade. Hypertension30, 905–911 (1997).
   PubMed Web of Science ®Google Scholar
• Moreau P, d’Uscio LV, Shaw S, Takase H, Barton M, Lüscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ETA-receptor antagonist. Circulation96, 1593–1597 (1997).
   PubMed Web of Science ®Google Scholar
• Oishi S, Sasaki M, Sato T. Elevated immunoreactive endothelin levels in patients with phaeochromocytoma. Am. J. Hypertens.7, 717–722 (1994).
   PubMed Web of Science ®Google Scholar
• Schiffrin EL, Deng LY, Sventek P, Day R. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J. Hypertens.15, 57–63 (1997).
   PubMed Web of Science ®Google Scholar
• Rossi GP, Colonna S, Pavan E et al. Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo. Circulation99, 1147–1155 (1999).
   PubMed Web of Science ®Google Scholar
• Cardillo C, Kilcoyne CM, Waclawiw M, Cannon RO 3rd, Panza JA. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension33, 753–758 (1999).
   PubMed Web of Science ®Google Scholar
• Amiri F, Virdis A, Neves MF et al. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation110, 2233–2240 (2004).
   PubMed Web of Science ®Google Scholar
• Barton M, Haudenschild CC, D’Uscio LV, Shaw S, Munter K, Luscher TF. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc. Natl Acad. Sci. USA9514367–14372 (1998).
   PubMed Web of Science ®Google Scholar
• Best PJM, McKenna CJ, Hasdai D, Holmes DRJ, Lerman A. Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolaemia. Circulation99, 1747–1752 (1999).
   PubMed Web of Science ®Google Scholar
• Bauersachs J, Fraccarollo D, Galuppo P, Widder J, Ertl G. Endothelin receptor blockade improves endothelial vasomotor dysfunction in heart failure. Cardiovasc. Res.47, 142–149 (2000).
   PubMed Web of Science ®Google Scholar
• Ihling C, Szombathy T, Bohrmann B, Brockhaus M, Schaefer HE, Loeffler BM. Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation104, 864–869 (2001).
   PubMed Web of Science ®Google Scholar
• Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N. Engl. J. Med.325, 997–1001 (1991).
   PubMed Web of Science ®Google Scholar
• Timm M, Kaski JC, Dashwood MR. Endothelin-like immunoreactivity in atherosclerotic human coronary arteries. J. Cardiovasc. Pharmacol.26, 442–444 (1995).
   Google Scholar
• Nichols W, Epstein BJ. Actions of selected cardiovascular hormones on arterial stiffness and wave reflections. Curr. Pharm. Des.15, 304–320 (2009).
   PubMed Web of Science ®Google Scholar
• McEniery CM, Qasem A, Schmitt M, Avolio AP, Cockcroft JR, Wilkinson IB. Endothelin-1 regulates arterial PWV in vivo. J. Am. Coll. Cardiol.42, 1975–1981 (2003).
   PubMed Web of Science ®Google Scholar
• Vuurmans TJ, Boer P, Koomans HA. Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and PWV in humans. Hypertension41, 1253–1258 (2003).
   PubMed Web of Science ®Google Scholar
• Demuth K, Blacher J, Guerin AP et al. Endothelin and cardiovascular remodelling in end-stage renal disease. Nephrol. Dial. Transplant.13, 375–383 (1998).
   PubMed Web of Science ®Google Scholar
• Karakitsos D, Patrianakos AP, Parthenakis FI et al. Altered proximal aortic stiffness and endothelin plasma levels in diabetic patients with end-stage renal disease. ASAIO J.53, 343–350 (2007).
   PubMed Web of Science ®Google Scholar
• Koyama H, Tabata T, Nishzawa Y, Inoue T, Morii H, Yamaji T. Plasma endothelin levels in patients with uraemia. Lancet1, 991–992 (1989).
   PubMed Web of Science ®Google Scholar
• Goddard J, Johnston NR, Cumming AD, Webb DJ. Fractional urinary excretion of endothelin-1 is reduced by acute ETB receptor blockade. Am. J. Physiol. Renal Physiol.293, F1433–F1438 (2007).
   Google Scholar
• Kohno M, Murakawa K, Yasunari K et al. Prolonged blood pressure elevation after endothelin administration in bilaterally nephrectomized rats. Metab. Clin. Exp.38, 712–713 (1989).
   PubMed Web of Science ®Google Scholar
• Orisio S, Benigni A, Bruzzi I et al. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int.43, 354–358 (1993).
   PubMed Web of Science ®Google Scholar
• Zoccali C, Leonardis D, Parlongo S, Mallamaci F, Postorino M. Urinary and plasma endothelin-1 in essential hypertension and in hypertension secondary to renoparenchymal disease. Nephrol. Dial. Transplant.10, 1320–1323 (1995).
   PubMed Web of Science ®Google Scholar
• Kohan DE. The renal medullary endothelin system in control of sodium and water excretion and systemic blood pressure. Curr. Opin. Nephrol. Hypertens.15, 34–40 (2006).
   PubMed Web of Science ®Google Scholar
• Kanai H, Okuda S, Kiyama S, Tomooka S, Hirakata H, Fujishima M. Effects of endothelin and angiotensin II on renal haemodynamics in experimental mesangial proliferative nephritis. Nephron64, 609–614 (1993).
   PubMed Web of Science ®Google Scholar
• Hocher B, Thöne-Reineke C, Rohmeiss P et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J. Clin. Invest.99, 1380–1389 (1997).
   PubMed Web of Science ®Google Scholar
• Benigni A, Remuzzi G. How renal cytokines and growth factors contribute to renal disease progression. Am. J. Kidney Dis.37, S21–S24 (2001).
   Google Scholar
• Barton M. Reversal of proteinuric renal disease and the emerging role of endothelin. Nat. Clin. Pract. Nephrol.4, 490–501 (2008).
   PubMedGoogle Scholar
• Gross ML, El-Shakmak A, Szábó A et al. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia46, 856–868 (2003).
   PubMed Web of Science ®Google Scholar
• Hocher B, Schwarz A, Reinbacher D et al. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron87, 161–169 (2001).
   PubMed Web of Science ®Google Scholar
• Vanêcková I, Kramer HJ, Bäcker A, Vernerová Z, Opocensky M, Cervenka L. Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats. Hypertension46, 969–974 (2005).
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Bakris GL. Review: insulin and endothelin: an interplay contributing to hypertension development? J. Clinical Endocrinol. Metabol.92, 379–385 (2007).
   PubMed Web of Science ®Google Scholar
• Ehmke H, Faulhaber J, Münter K, Kirchengast M, Wiesner RJ. Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. Hypertension33, 954–960 (1999).
   PubMed Web of Science ®Google Scholar
• Gourine AV, Gonon AT, Pernow J. Involvement of nitric oxide in cardioprotective effect of endothelin receptor antagonist during ischemia-reperfusion. Am. J. Physiol. Heart Circ. Physiol.280, H1105–H1112 (2001).
   Google Scholar
• Juan CC, Shen YW, Chien Y, Lin YJ, Chang SF, Ho LT. Insulin infusion induces endothelin-1-dependent hypertension in rats. Am. J. Physiol.287, 948–954 (2004).
   PubMedGoogle Scholar
• Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with Type II diabetes mellitus. Circulation106, 1783–1787 (2002).
   PubMed Web of Science ®Google Scholar
• Weber C, Schmitt R, Birnboeck H et al. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin-receptor antogonist, in healthy male volunteers. J. Clin. Pharmacol.39, 703–714 (1999).
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med.346, 896–903 (2002)
   PubMed Web of Science ®Google Scholar
• Fattinger K, Funk C, Pantze M et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther.69, 223–231 (2001).
   PubMed Web of Science ®Google Scholar
• Kurihara Y Kurihara H, Suzuki H et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature368, 703–710 (1994).
   PubMed Web of Science ®Google Scholar
• Kurihara Y, Kurihara H, Oda H et al. Aortic arch malformations and ventricular septal defects in mice deficient in endothelin-1. J. Clin. Invest.96, 293–300 (1995).
   PubMed Web of Science ®Google Scholar
• Kurihara Y, Kurihara H, Maemura K, Kuwaki T, Kumada M, Yazaki Y. Impaired development of the thyroid and thymus in endothelin-1 knockout mice. J. Cardiovasc. Pharmacol.26, 13–16 (1995).
   PubMed Web of Science ®Google Scholar
• Sever PS, Poulter NR, Elliott WJ et al. Blood pressure reduction is not the only determinant of outcome. Circulation113, 2754–2772 (2006).
   PubMed Web of Science ®Google Scholar
• Anand I, McMurray J, Cohn JN et al.; EARTH investigators. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet364, 327–354 (2004).
   PubMedGoogle Scholar
• Mylona P, Cleland JG. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Eur. J. Heart Fail.1, 197–200 (1999).
   PubMed Web of Science ®Google Scholar
• Luscher TF, Enseleit F, Pacher R et al. Hemodynamic and neurohumoral effects of selective endothelin A (ETA) receptor blockade in chronic heart failure: the Heart Failure ETA Receptor Blockade Trial (HEAT). Circulation106, 2666–2672 (2002).
   PubMed Web of Science ®Google Scholar
• Greene S, Nunley K, Weber S et al. ETA vs. ETB receptor selectivity of endothelin-1 receptor antagonists in human myocardial membranes (abstract). J. Am. Coll. Cardiol.47, 307A (2006).
   PubMed Web of Science ®Google Scholar